⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10316952 | 0.76 | — | — | |
| SCHEMBL9099368 | 0.65 | CYP1A1 (0.38) | — | |
| SCHEMBL8553982 | 0.65 | CYP1A1 (0.40) | — | |
| SCHEMBL29657636 | 0.65 | CYP1A1 (0.40) | — | |
| SCHEMBL4614504 | 0.64 | — | — | |
| SCHEMBL8720953 | 0.62 | — | — | |
| SCHEMBL9208 | 0.60 | CYP2B6 (0.43) | — | |
| SCHEMBL29364609 | 0.60 | CYP2B6 (0.43) | — | |
| SCHEMBL2289180 | 0.60 | CYP2B6 (0.43) | — | |
| SCHEMBL11135785 | 0.60 | CYP2B6 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346337-A1 | ANTICANCER ROCAGLAMIDE DERIVATIVES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-11 | — | — | US | claimed |
| EP-3863625-A1 | ANTICANCER ROCAGLAMIDE DERIVATIVES | The Research Institute at Nationwide Children's Hospital (US) | 2021-08-18 | — | — | EP | claimed |
| US-20210346337-A1 | ANTICANCER ROCAGLAMIDE DERIVATIVES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-11 | — | — | US | disclosed |
| EP-3863625-A1 | ANTICANCER ROCAGLAMIDE DERIVATIVES | The Research Institute at Nationwide Children's Hospital (US) | 2021-08-18 | — | — | EP | disclosed |
| US-8470824-B2 | Substituted naphto[2,3-f]quinoxaline-7,12-diones and pharmaceutical utility thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2013-06-25 | — | — | US | disclosed |
| US-8445492-B2 | Method for inhibiting growth of cancer cells and cell telomere and diseases of cell proliferation by using heteroannelated anthraquinone derivative compounds | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2013-05-21 | — | — | US | disclosed |
| US-8222287-B2 | Substituted anthra[1,2-D]imidazolediones and pharmaceutical utility thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-07-17 | — | — | US | disclosed |
| US-20110224218-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-09-15 | — | — | US | disclosed |
| US-20100256155-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-10-07 | — | — | US | disclosed |
| US-20100249143-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-09-30 | — | — | US | disclosed |
| US-20100210603-A1 | NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | TUNG ROGER D | 2010-08-19 | — | — | US | disclosed |
| US-6372778-B1 | AMINE HYDROXYALKYL SULFONAMIDE AS ENZYME INHIBITORS | VERTEX PHARMACEUTICALS, INCORPORATED | 2002-04-16 | — | — | US | disclosed |
| US-6004957-A | VIRICIDES FOR HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1999-12-21 | — | — | US | disclosed |
| US-5977137-A | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1999-11-02 | — | — | US | disclosed |
| US-5856353-A | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0885887-A2 | Sulfonamide inhibitors of HIV-Aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5783701-A | ANTI-HIV VIRICIDES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-07-21 | — | — | US | disclosed |
| US-5585397-A | VIRICIDES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1996-12-17 | — | — | US | disclosed |
| EP-0659181-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994005639-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-03-17 | — | — | WO | disclosed |